Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer

Fig. 2

Spautin-1 induces G0/G1 phase arrest via down-regulating Cyclin D1 in PCa cells. a Fluorescence-activated cell sorting analysis (FACS) was performed to analyze cell cycle distributions of PCa cells exposed to Spautin-1 or SKP2-C25 for 24 h. A summary of cell cycle distributions was shown from three independent experiments. b Western blot analysis was performed to detect the expression of CDK4, CDK2, Cyclin D1, P15 and P21 in PCa cells exposed to various doses of Spautin-1 (0, 5, 10, 20 μM) for 24 h (left), or Spautin-1 (10 μM) at various lengths of time (Right). c Western blot analysis was performed to detect the expression of CDK4, CDK2, Cyclin D1, USP10 and USP13 in PCa cells exposed to USP10 siRNA or USP13 siRNA for 48 h. d FACS was performed to analyze cell cycle distributions of PCa cells exposed to USP10 siRNA or USP13 siRNA for 48 h. e 22Rv1 and PC3 cells were transfected with HA-Cyclin D1 and/or FLAG-CDK2 for 48 h. Cell viability analysis was performed on the above cells exposed to Spautin-1 for 24 h. #P<0.05. f Western blot of CDK2 and Cyclin D1 to verified the overexpression in PC3 cells. Sp-1: Spautin-1

Back to article page